Pharmaceuticals
CNEY Wins a Large Activated Carbon Order
LISHUI, China, March 20, 2023 /PRNewswire/ -- CN Energy Group. Inc. (NASDAQ: CNEY) ("CNEY", or the "Company") today announced that its wholly-owned subsidiary, Zhejiang CN Energy New Materials Co., Ltd., has recently signed a contract to supply its high-quality wood-based activated carbon to a bu...
2023-03-20 20:30
1953
I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023
GAITHERSBURG, Md. and SHANGHAI, China, March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results ...
2023-03-20 20:00
2006
Guo Guangchang Stresses Healthy Corporate Development and Expresses Full Confidence in the Future
HONG KONG, March 20, 2023 /PRNewswire/ -- On 17 and 18 March, Guo Guangchang, Chairman of Fosun International, attended the 23rd Annual Conference of Yabuli China Entrepreneurs Forum 2023, and the 6th Shanghai Forum Themed Zhejiang Entrepreneurs in the World & the 11th Member Representative Confe...
2023-03-20 17:12
2469
ETANA HAS SECURED FINANCING FROM DEG, EAST VENTURES AND OTHER GLOBAL INVESTORS
JAKARTA, Indonesia, March 20, 2023 /PRNewswire/ -- PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has secured a new round of investment led by DEG followed by Yunfeng Capital, HighLight Capital and East Ventures. This round of financing will be used for fu...
2023-03-20 15:22
3055
Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting
– Five posters will showcase progress with multiple preclinical and clinical programs, including the clinical results ofATG-008 (mTORC1/2 inhibitor) and preclinical data ofATG-031 (anti-CD24 monoclonal antibody), ATG-037 (small molecule CD73 inhibitor), ATG-017 (ERK1/2 inhibitor), and ATG-034 (L...
2023-03-20 15:20
2004
Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in 'The Lancet' & 'European Heart Journal'
SEOUL, South Korea, March 17, 2023 /PRNewswire/ -- Hanmi Pharmaceuticals (128940.KS), a subsidiary of Hanmi Science (008930.KS) in Korea, announced that the results of large-scale clinical trial with Rosuzet have been published in 'The Lancet' and the 'European Heart Journal'. R&D-oriented pha...
2023-03-17 21:00
3674
Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion
* The company plans to begin construction in the first half of 2023 and commence operations in 2025 * As part of Samsung Biologics' second Bio Campus, Plant 5 will hold a manufacturing capacity of 180,000 liters, expanding the company's total site capacity to 784,000 liters upon its completio...
2023-03-17 19:25
3079
China's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical trial approval
BEIJING, March 17, 2023 /PRNewswire/ -- According the latest data released at the Clinical Trials Implied Approval section on the website ofChina's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), Likang Life Sciences (hereinafter referred to as "Likang") h...
2023-03-17 14:56
1996
YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ
YS Biopharma Ordinary Shares and Warrants to Trade on the Nasdaq Under Tickers "YS" and "YSBPW" NEW YORK, March 17, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (the "Company" or "YS Biopharma"), a global biopharmaceutical company focusing on new generations of vaccines and therapeutic biologic...
2023-03-17 04:30
2494
Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration according to Interim Findings from a Phase 2a Study in OA Patients
SEOUL, South Korea, March 16, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed that OLP-1002, a selective inhibitor of Nav1.7 sodium ion channel, showed strong analgesic efficacy and long therapeutic duration according to interim findings from a placebo-co...
2023-03-16 21:00
1869
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
INDIANAPOLIS, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 goze...
2023-03-16 20:28
1878
Bolstering Healthcare Quality in Malaysia with Renowned Flagship Hospitals
Malaysia's position as a safe and trusted destination for high-quality healthcare services is reinforced with the debut of flagship medical tourism hospitals in the country. KUALA LUMPUR, Malaysia, March 16, 2023 /PRNewswire/ -- Malaysia has debuted its first-of-its-kind Flagship Medical Tourism...
2023-03-16 16:12
4769
The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial
This is the first-ever global phase III trial for TGCT approved by NMPA and FDA. Pimicotinib（ABSK021）was granted BTD by FDA and CDE, discovered and developed byChina biotech。 SHANGHAI, March 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256. HK, referred to as "Abbis...
2023-03-16 10:00
3429
Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003
SUZHOU, China, March 16, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed with 2.1mg/kg in a Phase I clinical study (JSKN003-102) of JSKN003, an Anti-HER2 bispecific ADC. ADC drugs have the advantages of highly specific targeting of anti...
2023-03-16 09:58
2436
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
MELBOURNE, Australia, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga...
2023-03-16 08:28
2397
Akeso Reported 2022 Annual Results
* Strong sales fully demonstrated Akeso's commercialization ability: Products sales totaledRMB1,104.4 million, increasing 422% .开坦尼® (cadonilimab) recorded strong sales ofRMB546.3 million in its first six months of approval in China. 安尼可®(penpulimab injection, PD-1) recorded product sales ofRMB...
2023-03-16 08:26
3465
Ark Biopharmaceutical and Calibr, a Division of Scripps Research, Announce Co-development Collaboration on AK0705, a Potential First-in-Class Drug for Treating a Broad Spectrum of Respiratory Diseases, Including COPD
* Ark Biopharmaceutical will lead development activities for AK0705 with the goal of initiating clinical studies in 2024. * Calibr will continue to collaborate in the development of AK0705. * The collaboration is an extension of the current co-development collaboration. SHANGHAI, March 16, 2...
2023-03-16 07:50
3422
Bridge Biotherapeutics to Present Updated Preclinical Data of BBT-207 at the AACR 2023 Annual Meeting
* The abstract of BBT-207 preclinical studies is now available on the AACR
website
2023-03-15 21:00
2052
Everest Medicines to Announce Full-Year 2022 Financial Results on March 31, 2023
SHANGHAI, March 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will report financial results for the full year endedDecember 31, 20...
2023-03-15 20:45
2313
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
* Applications for physicians trained in Indonesia now open until April 15, 2023 12:00 AM * The Pharmaceutical Industry Fellowship Program provides physicians with the opportunity to experience the various steps of the drug development process ROCKVILLE, Md. and SEOUL, South Korea, March 15, ...
2023-03-15 19:00
1916
Week's Top Stories
Most Reposted
Agoda releases generative AI film to capture the joy of travel
[Picked up by 349 media titles]
2024-12-10 10:00
Singapore's IMAGINE AI: Largest Global Gathering to Shape the Future of Healthcare with AI Innovations
[Picked up by 316 media titles]
2024-12-06 10:41
Mastercard Economics Institute: APAC growth expected to hold steady in 2025; global policy resets may see shift in gears
[Picked up by 313 media titles]
2024-12-10 09:00Building Asia's Future: Omni HR Secures $7.4mn for HR Tech Expansion
[Picked up by 306 media titles]
2024-12-09 10:00
CCTV+: Yuhang Journey ǀ Follow Olivier to Explore Ancient Liangzhu and Savor Jingshan Tea
[Picked up by 283 media titles]
2024-12-08 20:07Most Read
Singapore's IMAGINE AI: Largest Global Gathering to Shape the Future of Healthcare with AI Innovations
2024-12-06 10:41
7026
Qi Biodesign Completes $75 Million in Total Funding to Drive Genome Editing Innovations
2024-12-06 20:15
6576
BROOKLYN NETS AND PHOENIX SUNS TO PLAY TWO PRESEASON GAMES IN MACAO IN OCTOBER 2025
2024-12-06 21:09
5816
